A Phase 3 interventional study of Everolimus and Everolimus placebo in Advanced Gastric Cancer, sponsored by Novartis Pharmaceuticals. Completed at 122 sites in 22 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-11-03.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies testing everolimus in Stomach Neoplasms — none open to participants now, none under way, none of them phase 3. Everolimus · Stomach Neoplasms.
Among the 13 studies testing everolimus in Stomach Neoplasms, this one has the largest enrollment, is one of 3 that started in 2009, is one of 2 in phase 3, and was the 4th registered.
3,406 studies on the registry are indexed under Stomach Neoplasms; 995 are open to participants now.
Browse Stomach Neoplasms studies →None of the 13 studies testing everolimus in Stomach Neoplasms is open now. The open studies under Stomach Neoplasms, anywhere →
Everolimus: first FDA approval 2009 (AFINITOR), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →
Of the 704 Stomach Neoplasms studies recruiting now, 376 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 28 take children under 18; 70 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 9 · Phase 3 2
First in 2002; this study’s year is marked. 3 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 656 is above the median of 66 across 2,505 interventional studies indexed under Stomach Neoplasms.
Median enrollment 49 across the 13 interventional studies. Of the 13 that completed or were terminated, 5 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 13 have an industry lead sponsor. The 8 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,721 studies on the registry; 222 are open to participants now.
Of its 586 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
13 studies in Stomach Neoplasms by Novartis: 1 open now, 1 under way, none of them phase 3. Of 12 finished, 2 (17%) have results posted.
Among the 13 studies in Stomach Neoplasms by Novartis, this one has the largest enrollment, is the only one that started in 2009, is the only one in phase 3, and was the 3rd registered.
Novartis’s Stomach Neoplasms studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 13 studies testing everolimus in Stomach Neoplasms, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 13 in Stomach Neoplasms:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is designed to assess the safety and efficacy of RAD001 monotherapy in patients with advanced gastric cancer which has progressed after one or two lines of prior chemotherapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All patients were randomized to receive everolimus + BSC. All patients orally took two 5 mg tablets of everolimus once daily. Therefore, all patients in the everolimus arm took a total daily dose of 10 mg. Best supportive care was in accordance with the local practice of an individual institution or center, and specifically excluded anti-cancer treatments.
Drug: Everolimus · Drug: Best Supportive Care (BSC)
All patients were randomized to receive placebo + BSC. All patients orally took two 5 mg tablets of matching placebo once daily. Therefore, all patients in the placebo receive matching tablets of total daily dose of 10 mg. Best supportive care was in accordance with the local practice of an individual institution or center, and specifically excluded anti-cancer treatments.
Drug: Everolimus placebo · Drug: Best Supportive Care (BSC)
Everolimus was formulated as tablets of 5 mg strength. In both treatment arms, the study drug was given by continuous oral daily dosing of 10 mg (2 tablets x 5 mg) each morning.
Also known as: RAD001
Placebo was formulated to be indistinguishable from the everolimus tablets, also formulated as tablets of 5 mg strength. In both treatment arms, the study drug was given by continuous oral daily dosing of 10 mg (2 tablets x 5 mg) each morning.
Best supportive care is defined as care in accordance with the local practice of an individual institution or center, specifically excluding anti-cancer treatments.
Overall Survival (OS)
The primary objective of this study was to compare OS between everolimus + best supportive care (BSC) and placebo + BSC. OS, was defined as the time from date of randomization to the date of death due to any cause. If at the analysis cut-off date a patient was not known to have died, survival was censored at the date of the last contact. OS was analyzed using the Kaplan Meier estimates method.
Time frame: 2.5 years
Progression Free Survival (PFS)
Progression free survival was defined as the time from the date of randomization to the date of the first documented disease progression or death due to any cause, where progression was based on Investigator assessment of baseline and post-baseline scans according to RECIST. Progression free survival was censored if no PFS event was observed before the first to occur out of (i) the cut-off date, or (ii) the date when a further anticancer therapy was started. The censoring date was the date of the last adequate tumor assessment before either of these two events occurred. If a PFS event was observed after two or more missing or non-evaluable tumor assessments, then the date of progression was censored at the date of the last adequate tumor assessment; for a PFS event observed after a single missing or non-evaluable tumor assessment, the actual date of disease progression was used. Anslsis was done using Kaplan-Meier estimates method.
Time frame: 2.5 years
Patient Reported Outcome (PRO): Time to Definitive Deterioration of European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire 30 (EORTC QLQ-C30) Scores
The EORTC QLQ-C30 global health status/quality of life sub-scale (QL) was pre-specified as the primary domain of interest, followed by physical functioning (PF), social functioning (SF) and emotional functioning (EF).The EORTC QLQ-C30 questionnaire, along with a module specific for gastric cancer patients (EORTC QLQ-STO22), was used to evaluate PRO. The QLQ-C30 has five function scales (physical, role, cognitive, emotional and social), three symptom scales (fatigue, pain and nausea/vomiting) and a global health status/quality of life scale. In addition, there are questions that assess specific symptoms. The QLQ-STO22 consists of 22 questions that make up five multi-item scales (dysphagia, pain, reflux, eating and anxiety) and four single-item scales (dry mouth, tasting, body image and hair loss).
Time frame: 2.5 years
Time to Definitive Deterioration of Eastern Cooperative Oncology Group Performance Status (ECOG PS) Score
The ECOG PS scale was used to classify patients according to their functional impairment, with scores ranging from 0 (fully active) to 5 (dead). An analysis of the time to definitive deterioration of the ECOG PS by one category of the score from baseline was performed. Definitive deterioration was defined as a definitive increase by one category from baseline in ECOG PS, with no later improvements observed during the course of the study. A single measure reporting an increase in ECOG PS is sufficient to consider it as a definitive worsening only if it was the last one available for the patient. Kaplan-Meier method was used to estimate the distribution function of time to definitive worsening.
Time frame: 2.5 years
Overall Response Rate (ORR)
ORR was defined as the proportion of patients with measurable disease in whom best overall response (OR) was either complete response (CR) or partial response (PR) according to RECIST criteria.
Time frame: 2.5 years
Everolimus Steady State Concentraions at Predose (Cmin) and Cmax at Week 5
Cmin is the minimum (trough) steady-state drug concentration in the blood during multiple dosing and Cmax is the maximum (peak) blood drug concentration after dose administration. Cmax is estimated as the maximum of C1h and C2H. C1h is 1 hour post-dose blood concentration and C2h is 2 hour post-dose blood concentration. Only valid pre-dose (Cmin), C1h, and C2h everolimus samples were included in the analysis. Valid pre-dose samples were confirmed blood samples collected at steady-state, collected immediately prior to dosing on the same study day, and collected at approximately 24 ± 4 hours after the previous dose and with no vomiting within the first 4 hours following the last dose. Valid C1h and C2h samples were confirmed blood samples collected at steady-state and within ± 1 hour window and with no vomiting within the first 4 hours following the current and previous dose.
Time frame: Week 5
Everolimus Steady State Concentraions at Predose (Cmin) and Cmax by Region Asia vs. Rest of the World (ROW) at Week 5
Cmin is the minimum (trough) steady-state drug concentration in the blood during multiple dosing and Cmax is the maximum (peak) blood drug concentration after dose administration. Cmax is estimated as the maximum of C1h and C2H. C1h is 1 hour post-dose blood concentration and C2h is 2 hour post-dose blood concentration. Only valid pre-dose (Cmin), C1h, and C2h everolimus samples were included in the analysis. Valid pre-dose samples were confirmed blood samples collected at steady-state, collected immediately prior to dosing on the same study day, and collected at approximately 24 ± 4 hours after the previous dose and with no vomiting within the first 4 hours following the last dose. Valid C1h and C2h samples were confirmed blood samples collected at steady-state and within ± 1 hour window and with no vomiting within the first 4 hours following the current and previous dose.
Time frame: Week 5
| Milestone | Everolimus 10mg/Daily | Placebo |
|---|---|---|
| Started | 439 | 217 |
| Discontinued study treatment | 428 | 217 |
| Completed | 11 | 0 |
| Not completed | 428 | 217 |
| Withdrew: Adverse event | 94 | 34 |
| Withdrew: Abnormal laboratory value | 1 | 0 |
| Withdrew: Withdrawal by subject | 20 | 7 |
| Withdrew: Lost to follow-up | 2 | 1 |
| Withdrew: Administrative problems | 2 | 0 |
| Withdrew: Death | 16 | 5 |
| Withdrew: Disease progression | 292 | 169 |
| Withdrew: Protocol violation | 1 | 1 |
The primary objective of this study was to compare OS between everolimus + best supportive care (BSC) and placebo + BSC. OS, was defined as the time from date of randomization to the date of death due to any cause. If at the analysis cut-off date a patient was not known to have died, survival was censored at the date of the last contact. OS was analyzed using the Kaplan Meier estimates method.
| Months | Everolimus 10mg/Daily | Placebo |
|---|---|---|
| Overall Survival (OS) | 5.39 (4.80 to 6.01) | 4.34 (3.81 to 5.49) |
Progression free survival was defined as the time from the date of randomization to the date of the first documented disease progression or death due to any cause, where progression was based on Investigator assessment of baseline and post-baseline scans according to RECIST. Progression free survival was censored if no PFS event was observed before the first to occur out of (i) the cut-off date, or (ii) the date when a further anticancer therapy was started. The censoring date was the date of the last adequate tumor assessment before either of these two events occurred. If a PFS event was observed after two or more missing or non-evaluable tumor assessments, then the date of progression was censored at the date of the last adequate tumor assessment; for a PFS event observed after a single missing or non-evaluable tumor assessment, the actual date of disease progression was used. Anslsis was done using Kaplan-Meier estimates method.
| Months | Everolimus 10mg/Daily | Placebo |
|---|---|---|
| Progression Free Survival (PFS) | 1.68 (1.51 to 1.94) | 1.41 (1.38 to 1.45) |
The EORTC QLQ-C30 global health status/quality of life sub-scale (QL) was pre-specified as the primary domain of interest, followed by physical functioning (PF), social functioning (SF) and emotional functioning (EF).The EORTC QLQ-C30 questionnaire, along with a module specific for gastric cancer patients (EORTC QLQ-STO22), was used to evaluate PRO. The QLQ-C30 has five function scales (physical, role, cognitive, emotional and social), three symptom scales (fatigue, pain and nausea/vomiting) and a global health status/quality of life scale. In addition, there are questions that assess specific symptoms. The QLQ-STO22 consists of 22 questions that make up five multi-item scales (dysphagia, pain, reflux, eating and anxiety) and four single-item scales (dry mouth, tasting, body image and hair loss).
| Months | Everolimus 10mg/Daily | Placebo |
|---|---|---|
| In QL score by at least 5 % compared to baseline | 1.51 (1.28 to 1.84) | 1.45 (1.05 to 1.68) |
| In PF score by at least 5 % compared to baseline | 1.35 (1.12 to 1.54) | 1.15 (1.02 to 1.64) |
| In SF score by at least 5 % compared to baseline | 1.87 (1.84 to 2.30) | 1.87 (1.64 to 2.46) |
| In EF score by at least 5 % compared to baseline | 1.84 (1.61 to 2.10) | 1.71 (1.41 to 1.87) |
The ECOG PS scale was used to classify patients according to their functional impairment, with scores ranging from 0 (fully active) to 5 (dead). An analysis of the time to definitive deterioration of the ECOG PS by one category of the score from baseline was performed. Definitive deterioration was defined as a definitive increase by one category from baseline in ECOG PS, with no later improvements observed during the course of the study. A single measure reporting an increase in ECOG PS is sufficient to consider it as a definitive worsening only if it was the last one available for the patient. Kaplan-Meier method was used to estimate the distribution function of time to definitive worsening.
| Months | Everolimus 10mg/Daily | Placebo |
|---|---|---|
| Time to Definitive Deterioration of Eastern Cooperative Oncology Group Performance Status (ECOG PS) Score | 2.30 (1.97 to 2.79) | 2.23 (1.87 to 2.92) |
ORR was defined as the proportion of patients with measurable disease in whom best overall response (OR) was either complete response (CR) or partial response (PR) according to RECIST criteria.
| Participants | Everolimus 10mg/Daily | Placebo |
|---|---|---|
| Measurable Disease | 379 | 191 |
| Complete Response (CR) | 1 | 0 |
| Partial Response (PR) | 16 | 4 |
| Overall Response Rate (ORR) | 17 | 4 |
Cmin is the minimum (trough) steady-state drug concentration in the blood during multiple dosing and Cmax is the maximum (peak) blood drug concentration after dose administration. Cmax is estimated as the maximum of C1h and C2H. C1h is 1 hour post-dose blood concentration and C2h is 2 hour post-dose blood concentration. Only valid pre-dose (Cmin), C1h, and C2h everolimus samples were included in the analysis. Valid pre-dose samples were confirmed blood samples collected at steady-state, collected immediately prior to dosing on the same study day, and collected at approximately 24 ± 4 hours after the previous dose and with no vomiting within the first 4 hours following the last dose. Valid C1h and C2h samples were confirmed blood samples collected at steady-state and within ± 1 hour window and with no vomiting within the first 4 hours following the current and previous dose.
| ng/mL | Everolimus 10mg/Daily | Everolimus 5 mg/Day |
|---|---|---|
| Pre-dose (Cmin) (n: 201,18) | 16.143 ± 10.7723 | 10.498 ± 6.1432 |
| Cmax (n: 218,16) | 72.775 ± 36.5435 | 37.269 ± 27.2086 |
Cmin is the minimum (trough) steady-state drug concentration in the blood during multiple dosing and Cmax is the maximum (peak) blood drug concentration after dose administration. Cmax is estimated as the maximum of C1h and C2H. C1h is 1 hour post-dose blood concentration and C2h is 2 hour post-dose blood concentration. Only valid pre-dose (Cmin), C1h, and C2h everolimus samples were included in the analysis. Valid pre-dose samples were confirmed blood samples collected at steady-state, collected immediately prior to dosing on the same study day, and collected at approximately 24 ± 4 hours after the previous dose and with no vomiting within the first 4 hours following the last dose. Valid C1h and C2h samples were confirmed blood samples collected at steady-state and within ± 1 hour window and with no vomiting within the first 4 hours following the current and previous dose.
| ng/mL | Everolimus 10mg/Daily | Everolimus 5mg/Day |
|---|---|---|
| Asia: Pre-dose (n:127, 11) | 16.804 ± 9.6163 | 9.921 ± 5.1565 |
| Asia: Cmax (n:132, 10) | 73.568 ± 34.1898 | 34.580 ± 26.8110 |
| Rest of the World: Pre-dose (n:74, 7) | 15.009 ± 12.5000 | 11.406 ± 7.8128 |
| Rest of the World: Cmax (n:86, 6) | 71.558 ± 40.0655 | 41.750 ± 29.8074 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Everolimus 10mg / Daily | — | 210/437 (48.1%) | 416/437 (95.2%) |
| Placebo | — | 89/215 (41.4%) | 193/215 (89.8%) |
| Event | Everolimus 10mg / Daily | Placebo |
|---|---|---|
| Abdominal painGastrointestinal disorders | 21/437 | 12/215 |
| Decreased appetiteMetabolism and nutrition disorders | 21/437 | 8/215 |
| VomitingGastrointestinal disorders | 14/437 | 10/215 |
| NauseaGastrointestinal disorders | 9/437 | 9/215 |
| AnaemiaBlood and lymphatic system disorders | 15/437 | 2/215 |
| General physical health deteriorationGeneral disorders | 14/437 | 4/215 |
| Gastrointestinal haemorrhageGastrointestinal disorders | 13/437 | 3/215 |
| AstheniaGeneral disorders | 12/437 | 6/215 |
| PneumoniaInfections and infestations | 12/437 | 4/215 |
| Intestinal obstructionGastrointestinal disorders | 5/437 | 5/215 |
| Event | Everolimus 10mg / Daily | Placebo |
|---|---|---|
| Decreased appetiteMetabolism and nutrition disorders | 202/437 | 76/215 |
| StomatitisGastrointestinal disorders | 173/437 | 22/215 |
| FatigueGeneral disorders | 146/437 | 63/215 |
| NauseaGastrointestinal disorders | 129/437 | 63/215 |
| DiarrhoeaGastrointestinal disorders | 112/437 | 33/215 |
| VomitingGastrointestinal disorders | 98/437 | 54/215 |
| AnaemiaBlood and lymphatic system disorders | 108/437 | 42/215 |
| Abdominal painGastrointestinal disorders | 90/437 | 49/215 |
| ConstipationGastrointestinal disorders | 92/437 | 41/215 |
| Weight decreasedInvestigations | 87/437 | 19/215 |
| Age, Continuous(years) | Everolimus 10mg/Daily | Placebo | Total |
|---|---|---|---|
| Mean | 60.3 ± 11.59 | 60.8 ± 11.61 | 60.4 ± 11.59 |
| Age, Customized(Participants) | Everolimus 10mg/Daily | Placebo | Total |
|---|---|---|---|
| < 65 years | 260 | 129 | 389 |
| >=65 years | 179 | 88 | 267 |
| Sex: Female, Male(Participants) | Everolimus 10mg/Daily | Placebo | Total |
|---|---|---|---|
| Female | 117 | 56 | 173 |
| Male | 322 | 161 | 483 |
| Race/Ethnicity, Customized(Participants) | Everolimus 10mg/Daily | Placebo | Total |
|---|---|---|---|
| Caucasian | 166 | 75 | 241 |
| Black | 3 | 1 | 4 |
| Asian | 251 | 126 | 377 |
| Native American | 0 | 1 | 1 |
| Other | 19 | 14 | 33 |
Showing the first 100 of 122 sites across 22 countries. Choose a country and city above to see the rest.
The record gives a start of Jul 2009, a primary completion of Jan 2014 and a completion of Jan 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2015, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Everolimus